论文部分内容阅读
34例极晚期、耐药的多发性骨髓瘤或淋巴瘤患者进入哌嗪二酮(Piperazinedione,Crystalline Antibiotic)的第Ⅱ期临床试验,每3～4周给予静脉注射一次,剂量为12毫克/平方米(骨髓受损者用9毫克/平方米)。9
Thirty-four patients with very advanced, drug resistant multiple myeloma or lymphoma who entered the Phase II clinical trial of piperazinedione (Crystalline Antibiotic) were given intravenously once every 3 to 4 weeks at a dose of 12 mg / M (bone marrow damage with 9 mg / square meter). 9